Veterans helping veterans: peer coaches aim to clarify prostate cancer screening choices
NCT ID NCT06549036
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether trained veteran peer navigators can help men aged 40-69 make informed choices about PSA screening for prostate cancer. Participants will receive a decision coaching session to understand the pros and cons of screening. The goal is to see if this approach reduces confusion and leads to decisions that match each veteran's values.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Veteran Peer Decision Coaching Session for PSA Screening
- What this could lead to
- If successful, this could show that peer coaching helps veterans make better-informed decisions about PSA screening, balancing benefits and risks.
- What could go wrong
- This is a small, early-stage behavioral study (228 participants) focused on decision-making, not on curing or treating cancer. Results may not apply to other groups or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VA NY Harbor Healthcare System, New York, NY
New York, New York, 10010-5011, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?